Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and survival among patients with refractory large B-cell lymphoma (LBCL) treated with conventional chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Neelapu, Sattva S., Locke, Frederick L., Bartlett, Nancy L., Lekakis, Lazaros J., Reagan, Patrick M., Miklos, David B., Jacobson, Caron A., Braunschweig, Ira, Oluwole, Olalekan O., Siddiqi, Tanya, Lin, Yi, Crump, Michael, Kuruvilla, John, Van Den Neste, Eric, Farooq, Umar, Navale, Lynn, DePuy, Venita, Kim, Jenny J., Gisselbrecht, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945634/
https://www.ncbi.nlm.nih.gov/pubmed/34478487
http://dx.doi.org/10.1182/bloodadvances.2020003848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945634/
https://www.ncbi.nlm.nih.gov/pubmed/34478487
http://dx.doi.org/10.1182/bloodadvances.2020003848

Ejemplares similares